Zai Lab (NASDAQ:ZLAB) Releases Quarterly Earnings Results

Zai Lab (NASDAQ:ZLAB) announced its quarterly earnings results on Thursday. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.18, Zacks reports. Zai Lab had a negative net margin of 41.86% and a negative return on equity of 27.43%. The company had revenue of $108.21 million for the quarter, compared to the consensus estimate of $107.90 million.

Here are the key takeaways from Zai Lab’s conference call:

• Zoci’s early first-line small cell lung cancer data were encouraging: In 33 evaluable patients, zoci plus atezolizumab produced an 81.8% confirmed response rate and estimated six-month progression-free survival of 81.9%, with grade 3 or higher zoci-related adverse events in 9.1%. The results are from a small early-stage study; Zai Lab plans a global phase III trial and is targeting a potential U.S. BLA submission in 2027.
• Zai Lab expects three registrational studies to be underway by year-end and anticipates two registrational readouts in 2027. For zoci, a potential accelerated-approval filing in second-line or later small cell lung cancer depends on the DLLEVATE interim analysis, while an epNEC filing would depend on forthcoming data and durability follow-up.
• China product revenue increased 2% sequentially, and the commercial business remained profitable. Management expects a return to year-over-year product revenue growth in 2027, citing potential NRDL access expansion and demand across priority brands; that outlook remains a company forecast.
• Zai Lab reported $659.7 million in cash at quarter-end and raised approximately $250 million in October. Management said stable R&D and SG&A expenses, operational efficiencies, and the financing support investment in its global pipeline.
• The company plans to present the first human data for its internally developed atopic dermatitis candidate ZL-1503 next week, with patient efficacy data and an IV-to-subcutaneous bridging study expected in 2027. Zai Lab is also advancing additional oncology and immunology assets, though these programs remain at earlier development stages.

Zai Lab Price Performance

ZLAB stock traded down $0.20 on Thursday, hitting $22.60. 813,969 shares of the company were exchanged, compared to its average volume of 885,390. The stock has a market capitalization of $2.57 billion, a price-to-earnings ratio of -13.22 and a beta of 0.77. Zai Lab has a twelve month low of $15.96 and a twelve month high of $27.50. The business’s fifty day moving average is $24.71 and its two-hundred day moving average is $21.00.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on ZLAB shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Zai Lab in a research note on Tuesday, October 27th. Wall Street Zen upgraded shares of Zai Lab from a “sell” rating to a “hold” rating in a report on Saturday, September 26th. Cantor Fitzgerald restated an “overweight” rating on shares of Zai Lab in a research report on Tuesday, October 6th. Finally, Citigroup boosted their price target on Zai Lab from $44.00 to $45.00 and gave the company a “buy” rating in a report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.25.

Insider Buying and Selling at Zai Lab

In other news, Director William Lis sold 8,506 shares of the company’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $25.00, for a total transaction of $212,650.00. Following the completion of the sale, the director directly owned 41,931 shares in the company, valued at $1,048,275. This represents a 16.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. In the last quarter, insiders have sold 9,385 shares of company stock valued at $235,145. 4.88% of the stock is owned by company insiders.

More Zai Lab News

Here are the key news stories impacting Zai Lab this week:

• Positive Sentiment: Zai Lab reported a Q3 loss of $0.41 per ADS, narrower than the roughly $0.58–$0.59 loss analysts expected. Revenue of $108.21 million also slightly exceeded the $107.90 million consensus. Earnings Flash
• Positive Sentiment: The company highlighted progress toward bringing its first internally developed medicines to patients globally; coverage also pointed to the pipeline’s potential first U.S. drug filing as a future catalyst. Company results and updates Pipeline report
• Negative Sentiment: Some coverage characterized the quarter as having a wider loss and lower revenue versus the year-ago period. Continued losses and revenue pressure could weigh on sentiment despite the beat against analyst estimates. Quarterly results coverage

Zai Lab Company Profile

Zai Lab Ltd. (NASDAQ:ZLAB) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. Its research and development activities have included oncology, autoimmune and inflammatory disorders, neuroscience, infectious diseases and other areas of significant unmet medical need.

Founded in 2014, Zai Lab has built its business through a combination of internally developed programs and licensing or collaboration agreements with international pharmaceutical and biotechnology companies.